BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant

Aziz Sheikh, Chris Robertson, Bob Taylor

Research output: Contribution to journalLetter

Abstract

We recently reported vaccine effectiveness for the BNT162b2 vaccine (Pfizer–BioNTech) and the ChAdOx1 nCoV-19 vaccine (AstraZeneca) against infection and hospitalization caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Scotland.1 At that time, the number of deaths was too small to allow estimation of vaccine effectiveness against death from infection with the delta variant.
Original languageEnglish
Pages (from-to)2195-2197
Number of pages3
JournalNew England Journal of Medicine
Volume385
Issue number23
Early online date20 Oct 2021
DOIs
Publication statusPublished - 2 Dec 2021

Keywords

  • vaccine effectiveness
  • delta variant
  • COVID-19

Fingerprint

Dive into the research topics of 'BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant'. Together they form a unique fingerprint.

Cite this